Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Wall Street Analysts Think Altimmune, Inc. (ALT) Could Surge 352%: Read This Before Placing a Bet
01:55pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
The mean of analysts' price targets for Altimmune, Inc. (ALT) points to a 352.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Altimmune to Participate at Two Upcoming Investor Conferences
11:30am, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will p
Altimmune to Participate at Two Upcoming Investor Conferences
07:30am, Friday, 03'rd Jun 2022
GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
11:30am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
07:30am, Tuesday, 31'st May 2022
GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of M
Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High?
01:55pm, Monday, 23'rd May 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 425.9% in Altimmune, Inc. (ALT). While the effectiveness of this highly sought-after metric is questionable, th
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
11:30am, Friday, 20'th May 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altim
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
07:30am, Friday, 20'th May 2022
GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmu
Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know
04:13pm, Wednesday, 18'th May 2022 Benzinga
Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00.
Shares of Altimmune are trading down 0.57% over the last 24 hour
Altimmune to Present at Upcoming Investor Conferences
11:30am, Monday, 16'th May 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will pa
Altimmune to Present at Upcoming Investor Conferences
07:30am, Monday, 16'th May 2022
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will partic
ALTIMMUNE INC (ALT) Q1 2022 Earnings Call Transcript
04:00pm, Thursday, 12'th May 2022 The Motley Fool
ALT earnings call for the period ending March 31, 2022.
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
Altimmune, Inc. (ALT) CEO Vipin K. Garg on Q1 2022 Results - Earnings Call Transcript
12:42pm, Thursday, 12'th May 2022
Altimmune, Inc. (NASDAQ:ALT ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Vipin K. Garg – President and Chief Executive Officer Richard Eisenstadt – Chief Financi
Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates
12:25pm, Thursday, 12'th May 2022 Zacks Investment Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 22.81% and 98.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
